Clovis Oncology

1. Clvs Stock Price

Oct 19, 2018 - Clovis Oncology, Inc. (NASDAQ: CLVS) today announced initial data from its ongoing Phase 2 TRITON2 clinical trial of Rubraca at the ESMO.

This article may rely excessively on sources, potentially preventing the article from being. Please help by replacing them with more appropriate to. (December 2016) Clovis Oncology: Website Clovis Oncology is a small pharmaceutical company which mainly markets products for treatment in oncology. Clovis was founded in 2009 and is headquartered in Boulder, Colorado. The company is a publicly traded company on under the symbol 'CLVS' and is in the NASDAQ Biotechnology Index with several products in its product pipeline. As of December 31, 2017 the company was not profitable and had incurred losses in each year since its inception in April 2009. Contents.

Pipeline Its products include: Rociletinib The company was developing, as a treatment for. A phase III trial was completed in April 2016 and had it been approved it would have competed with AstraZeneca's Tagrisso. According to the company web site as of November 2016 studies on the drug are no longer accepting new patients, but Clovis would continue to supply the drug to patients whose physicians had recommended continued treatment. In September 2018, the company and two former executives agreed to a $20M settlement with the on claims it exaggerated to investors the efficacy of Roci in patient trials. Rucaparib is a in Phase II and III clinical trials for advanced. Lucitanib is a.

It is also an inhibitor of and and has undergone clinical trials for advanced solid tumors. References. Retrieved 2016-01-04. Retrieved 4 January 2016. Retrieved 4 January 2016. 9 March 2015.

Archived from on March 9, 2015. Retrieved 4 January 2016. Clovis Oncology, Inc.

For the fiscal year ended December 31, 2017. Williams, Sean (23 December 2015). Fox Business. Retrieved 4 January 2016. Wallace, Alicia. Retrieved 4 January 2016. Archived from on 5 March 2016.

Retrieved 4 January 2016. Retrieved 2016-01-04. Retrieved 18 November 2016. Retrieved 2018-09-28. Retrieved 2018-09-28. Soria; et al. 'Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors'.

Annals of Oncology. 25 (11): 2244–51. CS1 maint: Explicit use of et al.

Clvs Stock Price

External links.

Corporate Profile Clovis’ product development programs generally target specific subsets of cancer, and the Company seeks to simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from its use. Through these collaborations, Clovis has the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovis’ regulatory and commercialization paths. Clovis believes this approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy.